Single serum progesterone determinations were made in 79 apparently normal women with a regular menstrual cycle. A normal range (40 subjects) was derived from the concentrations in the follicular phase and used to define an "'anovular" range for luteal phase values (nine out of 39 subjects). The remaining luteal phase values were used to construct an "ovular" range for the luteal phase and, within this rRnge, to define a group of values. (less than the 20th-centile) which could be described as a "defective luteal phase." The cut off limits between ovular and anovular and between normal and defective luteal phases were respectively two and four times the follicular phase median.
Introduction
The term "defective luteal phase" is used to describe the condition in which infertility is a result of inadequate secretion of progesterone by the corpus luteum.' 4 The amount of progesterone secreted is insufficient to maintain the appropriate milieu for the implantation of the blastocyst and early develop- 12) and from 39 women in the mid-luteal phase (day 0 minus 10 to day 0 minus 4 with respect to the next menstrual period). Ages ranged from 18 to 42 years. None of the subjects had any complaint relevant to menstruation or fertility, and-in each case there was a history of regular menstruation (range 26-35 days) for six cycles preceding the sample cycle. The date of onset of the last menstrual period was known accurately and none of the subjects was using a hormone preparation.
Serum samples were stored at -20°C until assayed. Serum progesterone was measured by a direct radioimmunoassay carried out at pH 4 to obviate the need for extraction. Standard or sample was mixed with a tracer of 1lot-OH-progesterone-glucuronyl-125I-iodotyramine and an antiserum to la-OH-progesterone-glucuronylbovine.serum albumin raised in a goat. After incubation for two and a half hours separation was achieved by adding 20% polyethylene glycol. The cross reaction of this system was < 1% for a wide range of steroids with the exception of 1ll-OH-progesterone and 11 P-OHprogesterone, which had potencies of 84% and 49% respectively.
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Results Table I proposed. This then defined a zone in which it was possible with reasonable confidence to state that ovulation had occurred but in which the values were low relative to the whole group of ovulatory subjects. If there is specific evidence of ovulation such as a mid-cycle peak of luteinising hormone then it is possible to define all relatively low values of progesterone as being the result of a "defective corpus luteum." Such evidence, however, is remarkably uncommon in routine clinical practice and very often a decision is sought solely on the basis of one measurement of progesterone without supporting data. Under these circumstances we propose the following: (a) that all values in' the follicular phase range should be treated as anovular; and (b) that a zone of values above this range, but which are still relatively low, should be selected as suggesting defective luteal function. We therefore propose an arbitrary limit at or close to the 20th centile of the ovular range (20 nmol/l; 6'3 ug/ml) ( figure) ; the range between this and the upper liniit of the follicular range constitutes the diagnosis of defective luteal phase.
We accept that these definitions are arbitrary and scientifically unsatisfactory. The study does not even show that there is anything abnormal (in terms of fertility) about the so called "abnormal" ranges, nor does it take into account variation 11 4 9 between successive cycles in the same subject. Nevertheless, with occasional exceptions4 9 11-13 there are very few published data which can be described as greatly superior. We do not seek to present arguments for or against the existence of the accepted clinical concepts. We are not aware of any previous attempts to define ranges in this manner, even though several cut off points have been described, ranging from 9-6 nmol/l (3-0 ng/ml)14 to 38 nmol/l (12-0 ng/ml).13 In addition, it is worth while re-emphasising that the principles of management of anovulation and defective luteal phase are quite different. There is well accepted and effective treatment for anovulation but little or no controlled evidence that current treatment of luteal phase deficiency is of any value. Thus it is of obvious therapeutic importance to distinguish the two conditions.
Another important feature of this study is the definition of the clinical cut off points as multiples of the follicular phase median. The purpose of this is as follows. It is well known that different assay systems (especially radioimmunoassay systems using different sets of reagents) give different numerical results. Thus an individual laboratory cannot rely entirely on published normal ranges or definitions of abnormality. Equally, the smaller unit cannot do its own clinical trial to define these ranges; even the quite simple investigation described here required appreciable time and effort. It should, however, be possible for any unit to collect a small group (10-20) of samples from apparently normal subjects in the follicular phase-a process aided by the fact that values are stable over this period and exact timing is not important. A median may be derived from this set of values and the multiples of the median then used to extrapolate an upper limit for the follicular phase or "anovular" values and a range for defective luteal function. For convenience, the limits so defined may be rounded to the nearest whole number. In this way the small unit can calculate with reasonable confidence a set of clinical action lines which would otherwise require a lengthy and tedious clinical study.
The 28 amino acid peptide vasoactive intestinal polypeptide has been found in nerve fibres throughout the body.' Evidence has been put forward that it functions as a neurotransmitter in several non-adrenergic, non-cholinergic physiological events.1 2 An essential part of the mechanism leading to penile erection is non-adrenergic, non-cholinergic relaxation of vascular and cavernous smooth muscle.36 The recent finding in the male genital tract ofnerves containing vasoactive intestinal polypeptide that seemed to innervate blood vessels,7-and the relaxant effect of the polypeptide on cavemous smooth muscle, suggest that it may act as a neurotransmitter in penile erection.
In the present study we investigated the local release of vasoactive intestinal polypeptide during erection and the effect of administering the polypeptide direct into the cavemous body.
